<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Traumatology and Orthopedics of Russia</journal-id><journal-title-group><journal-title xml:lang="en">Traumatology and Orthopedics of Russia</journal-title><trans-title-group xml:lang="ru"><trans-title>Травматология и ортопедия России</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2311-2905</issn><issn publication-format="electronic">2542-0933</issn><publisher><publisher-name xml:lang="en">Vreden National Medical Research Center of Traumatology and Orthopedics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">22</article-id><article-id pub-id-type="doi">10.21823/2311-2905-2016-0-1-33-45</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>Clinical studies</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">CLASSIFICATION AND ALGORITHM FOR DIAGNOSIS AND TREATMENT OF HIP PROSTHETIC JOINT INFECTION</article-title><trans-title-group xml:lang="ru"><trans-title>КЛАССИФИКАЦИЯ И АЛГОРИТМ ДИАГНОСТИКИ И ЛЕЧЕНИЯ ПЕРИПРОТЕЗНОЙ ИНФЕКЦИИ ТАЗОБЕДРЕННОГО СУСТАВА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Winkler</surname><given-names>T.</given-names></name><name xml:lang="ru"><surname>Винклер</surname><given-names>Т.</given-names></name></name-alternatives><address><country country="DE">Germany</country></address><bio xml:lang="en"><p>research group leader</p></bio><bio xml:lang="ru"><p>д-р мед. наук руководитель научной группы центра регенеративной терапии</p></bio><email>tobias.winkler@charite.de</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Trampuz</surname><given-names>A.</given-names></name><name xml:lang="ru"><surname>Трампуш</surname><given-names>А.</given-names></name></name-alternatives><address><country country="DE">Germany</country></address><bio xml:lang="en"><p>head of the center for septic surgery</p></bio><bio xml:lang="ru"><p>д-р мед. наук руководитель центра септической хирургии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Renz</surname><given-names>N.</given-names></name><name xml:lang="ru"><surname>Ренц</surname><given-names>Н.</given-names></name></name-alternatives><address><country country="DE">Germany</country></address><bio xml:lang="en"><p>head of the infectious diseases consultation service</p></bio><bio xml:lang="ru"><p>д-р мед. наук руководитель консультативной службы по лечению инфекционных болезней</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Perka</surname><given-names>C.</given-names></name><name xml:lang="ru"><surname>Перка</surname><given-names>К.</given-names></name></name-alternatives><address><country country="DE">Germany</country></address><bio xml:lang="en"><p>рrofessor, medical director</p></bio><bio xml:lang="ru"><p>профессор медицинский директор</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bozhkova</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Божкова</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>the head of the research department of prevention and treatment of wound infection and department of clinical pharmacology</p></bio><bio xml:lang="ru"><p>канд. мед. наук заведующая научным отделением профилактики и лечения раневой инфекции и отделением клинической фармакологии</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin</institution></aff><aff><institution xml:lang="ru">Центр костно-мышечной хирургии Шарите – университетский медицинский комплекс Берлина</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Vreden Russian Research Institute of Traumatology and Orthopedics</institution></aff><aff><institution xml:lang="ru">ФГБУ «Российский научно-исследовательский институт травматологии и ортопедии им. Р.Р. Вредена»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-06-24" publication-format="electronic"><day>24</day><month>06</month><year>2016</year></pub-date><volume>22</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>33</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2016-06-24"><day>24</day><month>06</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-06-24"><day>24</day><month>06</month><year>2016</year></date></history><permissions><copyright-year>2016</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://journal.rniito.org/jour/article/view/22">https://journal.rniito.org/jour/article/view/22</self-uri><abstract xml:lang="en"><p>Prosthetic joint infection (PJI) is the second common reason for revision surgery of the hip joint prosthesis. The rate of hip PJI is about 1% after primary surgery and it goes up to 4% or higher after revision surgery. In most cases, the main cause of this complication is an intraoperative bacterial contamination, rarer is a haematogenic one. An up-to-date diagnostic approach and clearly defined treatment strategy are required for the successful therapy of PJI. Based on the analysis of the scientific literature and own experience, an algorithm for diagnosis and treatment of this complication is proposed. A thoroughly obtained case history plays a predominant role in the diagnosis of PJI. Lack of the increased serum C-reactive protein cannot be considered as an exclusion criterion because in some cases, especially chronic infection, it can be within the normal range. Bacteriology lab tests of periprosthetic tissue biopsies and synovial fluid is the gold standard for the diagnosis. Novel methods such as ultrasound debridement of the removed prosthetic components have allowed to substantially increase the diagnostic sensitivity of bacteriology tests. This led to the discovery of PJI in some cases which before that were regarded as aseptic loosening. Visualization methods including MRI and scintigraphy play only a secondary role. The authors propose the classification of PJI for further determination of the treatment strategy which takes into account parameters such as biofilm maturity, prosthesis stability, the type of pathogen and soft tissue state for the decision on the treatment strategy. While desire to retain the implant is only justified in case of the immature biofilm, in most cases the infection can be cured only after the replacement of endoprosthesis. According to the proposed algorithm, patients undergo one- or two-stage procedure with a short or long interval. Antibiotics that are active against biofilm pathogens play an important role in the efficacy of the therapy. Selection of these antibiotics should be based on the results of bacteriology tests, preferably in collaboration with specialists in infectious diseases and microbiology.</p></abstract><trans-abstract xml:lang="ru"><p>Перипротезная инфекция (ППИ) является второй по частоте причиной ревизии эндопротезов тазобедренного сустава. Частота ППИ тазобедренного сустава составляет около 1% после первичных вмешательств и возрастает до 4% и выше после ревизионных операций. Причиной развития данного осложнения в большинстве случаев является интраоперационное инфицирование, реже - гематогенное. Для успешной терапии ППИ необходимы своевременная диагностика и четкая стратегия лечения. На основе анализа научной литературы и собственного опыта лечения ППИ предлагается алгоритм диагностики и лечения данного осложнения. Большое значение в диагностике ППИ имеет подробно собранный анамнез. Отсутствие повышения С-реактивного белка нельзя рассматривать как критерий исключения, так как в ряде случаев, особенно при хроническом течении инфекции, он может быть в пределах нормальных значений. «Золотым стандартом» диагностики является бактериологическое исследование образцов перипротезных тканей и синовиальной жидкости. Новые методы, такие как ультразвуковая обработка удаленных компонентов эндопротеза, позволили значительно повысить диагностическую значимость бактериологических исследований и в ряде случаев, ранее идентифицируемых как асептическое расшатывание эндопротеза, была диагностирована ППИ. Методы визуализации, такие как МРТ или сцинтиграфия, имеют лишь второстепенное значение. Авторы предлагают классификацию перипротезной инфекции для дальнейшего определения тактики лечения, которая учитывает такие параметры, как зрелость микробной биоплёнки, стабильность протеза, вид возбудителя и состояние мягких тканей. Стремиться сохранить протез можно только при незрелой биоплёнке, в большинстве случаев санация инфекции возможна только путем замены эндопротеза. В соответствии с предложенным алгоритмом пациентам назначается одноэтапный или двухэтапный метод лечения с коротким или длинным интервалом. Значимую роль в эффективности терапии отводят активным в отношении биоплёнки антибиотикам, выбор которых должен осуществляться с учетом результатов бактериологического исследования, желательно в междисциплинарном сотрудничестве со специалистами в области антимикробной химиотерапии и микробиологии</p></trans-abstract><kwd-group xml:lang="en"><kwd>hip arthroplasty</kwd><kwd>prosthetic joint infection</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эндопротезирование тазобедренного сустава</kwd><kwd>перипротезная инфекция</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Atkins BL, Athanasou N, Deeks JJ, Crook DW, Simpson H, Peto TE et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The OSIRIS Collaborative Study Group. J Clin Microbiol. 1998; 36(10):2932-2939.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Berbari E, Mabry T, Tsaras G, Spangehl M, Erwin PJ, Murad MH, et al. Inflammatory blood laboratory levels as markers of prosthetic joint infection: a systematic review and metaanalysis. J Bone Joint Surg. Am. 2010; 92(11):2102-2109.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J Bone Joint Surg. Am. 2005; 87(8):1746-1751.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Bozic KJ, Lau E, Kurtz S, Ong K, Rubash H, Vail TP, et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surg. Am. 2012; 94(9):794-800.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Corona P, Gil E, Guerra E, Soldado F, Amat C, Flores X, et al. Percutaneous interface biopsy in dry-aspiration cases of chronic periprosthetic joint infections: a technique for preoperative isolation of the infecting organism. Int Orthop. 2012; 36(6):1281-1286.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Corvec S, Portillo ME, Pasticci BM, Borens O, Trampuz A. Epidemiology and new developments in the diagnosis of prosthetic joint infection. Int J Artif Organs. 2012; 35(10):923-934.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Fink B, Gebhard A, Fuerst M, Berger I, Schafer P. High diagnostic value of synovial biopsy in periprosthetic joint infection of the hip. Clin Orthop Relat Res. 2013; 471(3):956-964.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Frommelt L. [Aspiration of joint fluid for detection of the pathogen in periprosthetic infection]. Orthopade. 2008; 37(10):1027-1034; quiz 35-36.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Furustrand Tafin U, Corvec S, Betrisey B, Zimmerli W, Trampuz A. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2012; 56(4):1885-1891.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Hsieh PH, Shih CH, Chang YH, Lee MS, Shih HN, Yang WE. Two-stage revision hip arthroplasty for infection: comparison between the interim use of antibiotic-loaded cement beads and a spacer prosthesis. J Bone Joint Surg. Am. 2004; 86-A(9):1989-1997.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Hwang JS, Beebe KS, Patterson FR, Benevenia J. Infected total femoral replacements: evaluation of limb loss risk factors. Orthopedics. 2011; 34(11):e736-740.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Ivancevic V, Perka C, Hasart O, Sandrock D, Munz DL. Imaging of low-grade bone infection with a technetium- 99m labelled monoclonal anti-NCA-90 Fab’ fragment in patients with previous joint surgery. Eur J Nuclr Med Molec Imag. 2002; 29(4):547-551.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Janz V, Wassilew GI, Hasart O, Matziolis G, Tohtz S, Perka C. Evaluation of sonicate fluid cultures in comparison to histological analysis of the periprosthetic membrane for the detection of periprosthetic joint infection. Int Orthop. 2013; 37(5):931-936.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Janz V, Bartek B, Wassilew GI, Stuhlert M, Perka CF, Winkler T. Validation of synovial aspiration in girdlestone hips for detection of infection persistence in patients undergoing 2-stage revision total hip arthroplasty. J Arthroplasty. 2016; 31(3):684-687.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Jung J, Schmid NV, Kelm J, Schmitt E, Anagnostakos K. Complications after spacer implantation in the treatment of hip joint infections. Int J Med Sci. 2009; 6(5):265-273.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Krenn V, Morawietz L, Kienapfel H, Ascherl R, Matziolis G, Hassenpflug J, et al. [Revised consensus classification: Histopathological classification of diseases associated with joint endoprostheses]. Z Rheumatol. 2013; 72(4):383-392.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012; 27(8 Suppl):61-65 e1.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Lange J, Troelsen A, Thomsen RW, Soballe K. Chronic infections in hip arthroplasties: comparing risk of reinfection following one-stage and two-stage revision: a systematic review and meta-analysis. Clin Epidemiol. 2012; 4:57-73.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Langlais F, Kerboull M, Sedel L, Ling RS. The ‘French paradox. J Bone Joint Surg. Br. 2003; 85(1):17-20.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Langlais F. Can we improve the results of revision arthroplasty for infected total hip replacement? J Bone Joint Surg. Br. 2003; 85(5):637-640.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Love C, Marwin SE, Palestro CJ. Nuclear medicine and the infected joint replacement. Sem Nucl Med. 2009; 39(1):66-78.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Maderazo EG, Judson S, Pasternak H. Late infections of total joint prostheses. A review and recommendations for prevention. Clin Orthop Rel Res. 1988; (229):131-42.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Miller TT. Imaging of hip arthroplasty. Eur J Radiol. 2012; 81(12):3802-3812.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Morawietz L, Classen RA, Schroder JH, Dynybil C, Perka C, Skwara A et al. Proposal for a histopathological consensus classification of the periprosthetic interface membrane. J Clin Pathol. 2006; 59(6):591-597.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Mulcahy H, Chew FS. Current concepts of hip arthroplasty for radiologists: part 2, revisions and complications. AJR Am J Roentgenol. 2012; 199(3):570-580.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Muller M, Morawietz L, Hasart O, Strube P, Perka C, Tohtz S. Diagnosis of periprosthetic infection following total hip arthroplasty--evaluation of the diagnostic values of preand intraoperative parameters and the associated strategy to preoperatively select patients with a high probability of joint infection. J Orthop Surg Res. 2008; 3:31.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Murdoch DR, Roberts SA, Fowler Jr VG, Jr., Shah MA, Taylor SL, Morris AJ, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2001; 32(4):647-649.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Oliva A, Furustrand Tafin U, Maiolo EM, Jeddari S, Betrisey B, Trampuz A. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2014; 58(3):1284-1293.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29. Parvizi J, Adeli B, Zmistowski B, Restrepo C, Greenwald AS. Management of periprosthetic joint infection: the current knowledge: AAOS exhibit selection. J Bone Joint Surg. Am. 2012; 94(14):e104.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30. Perka C, Haas N. [Periprosthetic infection]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen. Medizen. 2011; 82(3):218-226.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31. Portillo ME, Salvadó M, Alier A, Sorli L, Martínez S, Horcajada JP et al. Prosthesis failure within two years of implantation is highly predictive for infection. Clin Orthop Relat Res. 2013; 471(11):3672-3678.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32. Schinsky MF, Della Valle CJ, Sporer SM, Paprosky WG. Perioperative testing for joint infection in patients undergoing revision total hip arthroplasty. J Bone Joint Surg. Am. 2008; 90(9):1869-1875.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33. Sculco TP. The economic impact of infected total joint arthroplasty. Instr. course Lect. 1993; 42: 349-51.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34. Senthi S, Munro JT, Pitto RP. Infection in total hip replacement: meta-analysis. Int Orthop. 2011; 35(2):253-260.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35. Spangehl MJ, Masri BA, O’Connell JX, Duncan CP. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>of two hundred and two revision total hip arthroplasties. J Bone Joint Surg. Am. 1999; 81(5):672-683.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>36. Strobel K, Stumpe KD. PET/CT in musculoskeletal infection. Semin Musculoskelet Radiol. 2007; 11(4): 353-364.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>37. Tohtz SW, Muller M, Morawietz L, Winkler T, Perka C. Validity of frozen sections for analysis of periprosthetic loosening membranes. Clin Orthop Relat Res. 2010; 468(3):762-768.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>38. Trampuz A, Piper KE, Jacobson MJ, Hanssen AD, Unni KK, Osmon DR, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med. 2007; 357(7):654-663.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>39. Trampuz A, Zimmerli W. Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis. Curr Infect Dise Rep. 2008; 10(5):394-403.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>40. Trampuz A, Perka C, Borens O. [Prosthetic joint infection: new developments in diagnosis and treatment]. Dtsch Med Wochenschr. 2013; 138(31-32):1571-1573.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>41. Winkler H. Bone grafting and one-stage revision of THR – biological reconstruction and effective antimicrobial treatment using antibiotic impregnated allograft bone. Hip Int. 2012; 22 Suppl 8:S62-68.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>42. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004 ;351(16):1645-1654.</mixed-citation></ref></ref-list></back></article>
